OUR PIPELINE

Focusing on making a difference in rare diseases with significant unmet need

Program Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3 Approved

FILSPARI® (sparsentan)1

 IgAN
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Sparsentan2

 		FSGS
Preclinical
Phase 1
Phase 2
Phase 3

Pegtibatinase (TVT-058)3

 		HCU
Preclinical
Phase 1
Phase 2
Phase 3

ALGS Collaboration

 		ALGS
Preclinical
Phase 1
Phase 2
Phase 3

1 On February 17, 2023, we announced that the FDA granted approval of sparsentan under the accelerated pathway for the reduction of proteinuria in IgAN. Read the press release>

2 On May 1, 2023, we announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan. Read the press release>

3 Pegtibatinase (TVT-058) is currently in a Phase 1/2 clinical study.

FSGS: focal segmental glomerulosclerosis; IgAN: IgA nephropathy; HCU: classical homocystinuria; ALGS: Alagille syndrome

*On September 5, 2023, Travere Therapeutics announced that Mirum Pharmaceuticals acquired all of Travere’s rights and assets related to Cholbam® and Chenodal®. For more information, please visit mirumpharma.com.